Trinity Biotech (TRIB) Cash from Investing Activities (2021 - 2024)

Trinity Biotech has disclosed Cash from Investing Activities across 4 years of filings, most recently posting -$2.7 million for Q4 2024.

• Cash from Investing Activities for Q4 2024 came in at -$2.7 million, down 207.07% year-over-year; the trailing twelve-month figure through Dec 2024 was -$5.7 million (down 33.31% YoY), and the FY2025 annual result was -$6.2 million, up 72.91% from the prior year.
• Cash from Investing Activities came in at -$2.7 million for Q4 2024 at Trinity Biotech, down from -$891000.0 in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of -$1801.0 in Q2 2022 to a low of -$2.7 million in Q4 2024.
• The 4-year median for Cash from Investing Activities is -$1.0 million (2022), against an average of -$1.2 million.
• Across the five-year window, Cash from Investing Activities jumped 54.02% in 2022 and slumped 207.07% in 2024, its largest moves.
• Trinity Biotech's Cash from Investing Activities stood at -$2.5 million in 2021, then jumped by 54.02% to -$1.1 million in 2022, then rose by 21.7% to -$891000.0 in 2023, then plunged by 207.07% to -$2.7 million in 2024.
• The last three Cash from Investing Activities figures came in at -$2.7 million (Q4 2024), -$891000.0 (Q4 2023), and -$886000.0 (Q3 2023), per Business Quant data.